The Company is currently developing a range of pharmaceutical product projects that are mostly based on its Multi Matrix MMX® technology. This technology allows the delivery of active pharmaceutical ingredients mainly into the lumen of the colon through tablet erosion in a delayed and controlled manner. This has the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.
The Company's proprietary clinical development pipeline specifically addresses innovative treatments for Colon Diseases, with the group's first product Lialda® launched in the US and EU, with UCERIS® launched in the US and Cortiment® launched in several European countries and other parts of the world and with the nutraceutical Zacol NMX® launched for the local market in Italy and in selected Eastern European countries. In September 2015 the FDA approved the Company’s novel Eleview™, a submucosal injectable composition intended to make the excision of polyps and adenomas easier. Both LuMeBlue and Zemcolo have successfully completed their phase III trials and the dossiers to file the NDA both in the USA and Europe are being prepared The Company’s developments in skin diseases were transferred to a separate Company Cassiopea SpA and the Company reduced its participation to 45.1% by executing an IPO on the Swiss Stock Exchange (SIX) in July 2015.